References

Devinsky O et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. NEJM 2017;376(21):2011–2020.

Devinsky O et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. NEJM 2018;378(20):1888–1897.

Thiele EA et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet 2018;391(10125):1085–1096.

Thiele EA et al. Cannabidiol in patients with tuberous sclerosis complex–associated seizures. JAMA Neurol 2021;78(3):285–292.

Leweke FM et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012;2:e94.

McGuire P et al. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. Am J Psychiatry 2018;175(3):225–231.

Boggs DL et al. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia: a randomized placebo controlled trial. Psychopharmacology 2018;235(7):1923–1932.

Bhattacharyya S et al. Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis. JAMA Psychiatry 2018;75(11):1107–1117.

Bergamaschi MM et al. Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients. Neuropsychopharmacology 2011;36(6):1219–1226.

Crippa JA et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011;25(1):121–130.

Linares IM et al. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry 2019;41(1):9–14.

Bonn-Miller MO et al. The Short-Term Impact of 3 Smoked Cannabis Preparations versus Placebo on PTSD Symptoms: A Randomized Crossover Clinical Trial. PLoS One 2021;16(3):e0246990.

Hurd YL et al. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. Am J Psychiatry 2019;176(11):911–922.

Freeman TP et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry 2020;7(10):865–874.

Aran A et al. Cannabidiol-Based Medical Cannabis in Children with Autism – a Retrospective Feasibility Study. Neuropsychopharmacology 2019.

Beal JE et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995;10(2):89–97.

Tramèr MR et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323(7303):16–21.

Whiting PF et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA 2015;313(24):2456–2473.

Müller-Vahl KR et al. Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol (THC): no influence on neuropsychological performance. Pharmacopsychiatry 2003.

Collin C et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14(3):290–296.

Novotna A et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18(9):1122–1131.

Johnson JR et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010;39(2):167–179.

Portenoy RK et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 2012;13(5):438–449.

Lichtman AH et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manage 2018;55(2):179–188.

Elms L et al. Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series. J Altern Complement Med 2019.

Narayan AJ et al. Cannabidiol for moderate–severe insomnia: a randomized controlled pilot trial of 150 mg nightly dosing. J Clin Sleep Med 2024;20(5):753–763.

Aychman MM et al. Cannabidiol's neuroprotective properties and potential treatment of traumatic brain injuries. Front Neurol 2023.

Epidyolex 100 mg/ml oral solution — UK Summary of Product Characteristics (SmPC). Medicines.org.uk.

European Medicines Agency. Epidyolex EPAR: medicine overview.

Thiele EA et al. Cannabidiol in tuberous sclerosis complex–associated seizures. JAMA Neurology 2021.

O'Brien TJ et al. Adjunctive transdermal cannabidiol for adults with focal epilepsy: a randomized clinical trial. JAMA Network Open 2022.

EpiFOS trial. Cannabidiol Oral Solution for Focal-Onset Seizures. ClinicalTrials.gov NCT07233239.

Gao Y et al. Novel cannabidiol aspartame combination treatment (JW-100) significantly reduces ISGA score in atopic dermatitis. J Cosmetic Dermatology 2022.

Casedas G et al. Cannabidiol: a systematic review of clinical evidence. 2024.

Puaratanaarunkon T et al. Topical cannabidiol-based treatment for psoriasis: a dual-centre randomized placebo-controlled study. JEADV 2022.

Yoo EH et al. Cannabinoids and their receptors in skin diseases. Int J Mol Sci 2023.

Botanix Pharmaceuticals. BTX 1503 acne Phase 2 study results presentation. 2019.

Ali A, Akhtar N. The safety and efficacy of 3% Cannabis seeds extract cream for reduction of human cheek skin sebum and erythema content. Pak J Pharm Sci 2015.

Peyravian N et al. The anti-inflammatory effects of cannabidiol on acne. 2022.

Dvorak M et al. Topical/transdermal cannabidiol systematic review. Cannabis and Cannabinoid Research 2022.

Effect of CBD-Based Vaginal Suppositories on Menopausal Symptoms. ClinicalTrials.gov NCT06804889.

Costantino D et al. Vaginal hyaluronic acid suppositories in postmenopausal vaginal atrophy. Climacteric 2008.

DREAMLAND Study. Cannabidiol-enriched extract oil for postoperative chronic pelvic pain secondary to endometriosis. 2026.

ENDOCAN-1. Pilot randomized controlled trial of MRX1 CBD for endometriosis-associated pain.

Whitaker LHR et al. Endometriosis: cannabidiol therapy for symptom relief. Trends Pharmacol Sci 2024.

Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo-Controlled Trial. ClinicalTrials.gov NCT05632627.